Sanara MedTech (NASDAQ:SMTI) Stock Rating Upgraded by Freedom Capital

Sanara MedTech (NASDAQ:SMTI) was upgraded by research analysts at Freedom Capital to a “strong-buy” rating in a report issued on Wednesday,Zacks.com reports.

Several other brokerages have also issued reports on SMTI. Wall Street Zen raised shares of Sanara MedTech from a “hold” rating to a “buy” rating in a report on Saturday, May 16th. Lake Street Capital started coverage on shares of Sanara MedTech in a research report on Wednesday, April 15th. They issued a “buy” rating and a $32.00 target price on the stock. Zacks Research raised shares of Sanara MedTech from a “strong sell” rating to a “hold” rating in a research note on Wednesday, June 10th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Sanara MedTech in a report on Tuesday, April 21st. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $34.00.

Sanara MedTech Stock Performance

NASDAQ:SMTI opened at $21.22 on Wednesday. Sanara MedTech has a twelve month low of $16.05 and a twelve month high of $35.95. The company has a quick ratio of 2.05, a current ratio of 2.28 and a debt-to-equity ratio of 6.59. The stock’s 50-day simple moving average is $20.62 and its 200 day simple moving average is $21.01. The firm has a market capitalization of $194.38 million, a PE ratio of -5.63 and a beta of 1.21.

Sanara MedTech (NASDAQ:SMTI) last issued its earnings results on Tuesday, March 24th. The company reported $0.04 EPS for the quarter, missing the consensus estimate of $0.11 by ($0.07). The business had revenue of $27.55 million for the quarter, compared to analyst estimates of $27.90 million. Sanara MedTech had a negative return on equity of 3.19% and a negative net margin of 31.23%. On average, analysts anticipate that Sanara MedTech will post 0.16 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Royal Bank of Canada boosted its position in Sanara MedTech by 11.7% during the 1st quarter. Royal Bank of Canada now owns 131,389 shares of the company’s stock worth $2,257,000 after buying an additional 13,746 shares during the period. Renaissance Technologies LLC increased its position in Sanara MedTech by 72.0% in the 1st quarter. Renaissance Technologies LLC now owns 64,680 shares of the company’s stock valued at $1,111,000 after acquiring an additional 27,078 shares during the period. Hsbc Holdings PLC raised its stake in shares of Sanara MedTech by 12.1% during the first quarter. Hsbc Holdings PLC now owns 17,283 shares of the company’s stock valued at $301,000 after acquiring an additional 1,869 shares during the last quarter. Stonebridge Wealth Management LLC raised its stake in shares of Sanara MedTech by 1.5% during the first quarter. Stonebridge Wealth Management LLC now owns 136,899 shares of the company’s stock valued at $2,352,000 after acquiring an additional 1,965 shares during the last quarter. Finally, Rockefeller Capital Management L.P. acquired a new position in shares of Sanara MedTech during the fourth quarter worth $299,000. Institutional investors own 8.10% of the company’s stock.

Sanara MedTech Company Profile

Sanara MedTech is a medical technology company focused on developing and commercializing innovative devices for ear, nose and throat (ENT) healthcare. The company’s core offering centers on minimally invasive sinus dilation systems designed to treat chronic sinusitis and related conditions. These products leverage balloon catheter technology to expand sinus pathways and improve patient outcomes while reducing recovery times. In addition to sinus solutions, the portfolio extends to procedural tools and implants for otology and cranial applications.

With its legacy rooted in the assets of a former Johnson & Johnson business, Sanara MedTech combines decades of research and development in ENT therapies.